Terns Pharmaceuticals Inc (TERN) saw an uptrend of 10.65% in the recent trading with $993690.0 being its most recent. The current price level -62.63% lower than the highest price of $11.40 marked by the stock while trading over the past 52-weeks, whereas it is 128.42% higher than the lowest price of $1.87 the company dropped to over past 52-weeks. The latest news story on TERN appeared in (GlobeNewswire) under the title “Terns Pharmaceuticals Presents Positive Data from Phase 1 Study of TERN-601 Once-daily Oral GLP-1R Agonist for Treatment of Obesity at 85th Annual American Diabetes Association Scientific Sessions” on Jun-23-25.
Do analysts rate it as a buy, sell or hold?
Irrespective of recent performance, what’s important is what the future holds. In uncertain economic times, a clear picture is difficult to get. Analysts generally have a good understanding of the market works, which gives them a leg up in making predictions. Currently, the stock has been recommended as Strong Buy by 5 of the brokerage firms. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 1.44 for the stock.
Terns Pharmaceuticals Inc Earnings – What Happened With TERN
Coming around sales and income figures on TERN Stock Income Statement, public trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor.
Terns Pharmaceuticals Inc – Insider Activity and Holdings
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 87.30 million. TERN does have institutional investors; and they hold 78.77% of the stock.
As on 2024-06-30, ORBIMED ADVISORS LLC was the top most holder in Terns Pharmaceuticals Inc (NASDAQ:TERN) with an ownership of 7.62 million shares of the company or 10.2326 of the stake worth $51.89 million. The filing also reveals VIVO CAPITAL, LLC as the second largest holder in the company with a control over 8.3038 of the outstanding shares. Its stake is worth $42.11 million for having 6.18 million shares in hand.
DEEP TRACK CAPITAL, LP also came holding a key position in the company during the recent quarter and it now holds 8.1923 of the outstanding shares. With this there are now 190.0 institutions which have possession in TERN’s shares.
Key Metrics forTERN
The liquidity is a key characteristic of any stock and is the main point of focus of both short-term as well as long term investors before start trading into a stock. In recently reported quarter, Terns Pharmaceuticals Inc has a debt to equity ratio of 0.00.
Technical Analysis of Terns Pharmaceuticals Inc (NASDAQ:TERN) stock
To comprehend better with the trade moves and investors’ behavior, exploring the short, medium and long term technical indicators along with average volume of a stock is an effective way to make use of. When looking into those indicators for Terns Pharmaceuticals Inc (TERN), we notice that the stock’s 20-day average volume is at 946,870 shares and 50% of short term indicators are suggesting the stock as Buy. And to end with, TERN’s 100-day average volume are 1,025,169 shares.
